Crohn's Disease

SAN DIEGO — Anxiety left unaddressed in the context of inflammatory bowel disease care “will impact the disease course and outcomes,” according to a presenter at Digestive Disease Week 2022.

SAN DIEGO — The risk for postoperative recurrence of Crohn’s disease after ileocolic resection did not increase among older patients compared with a younger cohort, according to research presented at Digestive Disease Week 2022.

SAN DIEGO — Vedolizumab and ustekinumab associated with a lower risk for infection-related hospitalizations compared with anti-tumor necrosis factor agents in patients who initiated inflammatory bowel disease therapy at an older age.

SAN DIEGO — Older patients with inflammatory bowel disease who were treated with biologics exhibited a lower incidence of dementia compared with those never treated with biologics, according to data presented at Digestive Disease Week 2022.

SAN DIEGO — Obesity was not linked to hospitalization, surgery or serious infection among a subset of biologic-treated patients with inflammatory bowel disease, according to research presented at Digestive Disease Week 2022.

SAN DIEGO — Paternal exposure to the majority of therapies for inflammatory bowel disease did not increase the risk for adverse neonatal outcomes, according to data from a small patient subset presented at Digestive Disease Week 2022.

SAN DIEGO — Though patients with inflammatory bowel disease have impaired humoral response after SARS-CoV-2 vaccinations, cellular responses were maintained and comparable to those of health care workers, according to study results.

SAN DIEGO — In this video exclusive, Remo Panaccione, MD, of the University of Calgary, discussed a study assessing the safety and efficacy of Tremfya in patients with moderately to severely active Crohn’s disease.

SAN DIEGO — Patients with inflammatory bowel disease had a higher incidence of herpes zoster than the general population, demonstrating a need for preventive measures, according to research presented at Digestive Disease Week 2022.

SAN DIEGO — A novel tool for educating patients with inflammatory bowel disease on biologic therapies failed to improve upon standard education with regard to shared decision-making, according to data presented at Digestive Diseases Week.